Valeant: At Worst, A Good Catalyst Play

  • Valeant Pharmaceuticals expects the FDA decision for Latanoprostene Bunod in August.
  • For new investors, this may be an opportunity for some quick gains.
  • For old hands suffering from the stock’s two-year depressive run, these are signs of better times.

By S. Mitra, MBA (ISB)

For those who invested in Valeant Pharmaceuticals International Inc. (NYSE:VRX) in early 2015 trying to get on its obvious bull run at that time, holding on to Valeant beyond the now-infamous Hillary Clinton speech of September 2015 was perhaps the worst mistake of your investment life. The stock went from over $250 to below $75 in a month’s time, and if that was not enough, Ms Clinton was at it again in March 2016, this time directly attackingValeant by name. The stock fell further, to near $25, by March 18, a few weeks after Hillary’s speech - and the stock has never looked back since in its incessant run towards oblivion.

The full post is available to investor members only. Subscribe here.

title here

bulleted summary here

first para as teaser here

The full post is available to investor members only. Subscribe here.